NCT02828540View on ClinicalTrials.gov

Clinical Trial to Assess the Efficacy and to Evaluate Safety of HT047 in Patients With Acute Ischemic Stroke

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

August 4, 2016

Primary Completion Date

August 3, 2018

Study Completion Date

August 3, 2018

Conditions
Ischemic Stroke
Interventions
DRUG

HT047 High-dose group

HT047 2250mg, three times a day dosing schedule, 3 tablets per dose

DRUG

HT047 Low-dose group

HT047 1500mg, three times a day dosing schedule, 3 tablets per dose

DRUG

Placebo

placebo having the same appearance as HT047 Tab. 250mg

Trial Locations (8)

10475

Myongji Hospital, Goyang-si

11923

Hanyang University Guri Hospital, Guri-si

18450

Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si

21565

Gachon University Gil Medical Center, Incheon

61453

Chosun University Hospital, Gwangju

02447

Kyung Hee University Hospital, Seoul

04763

Hanyang University Medical Center, Seoul

05278

Kyung Hee University Hospital at Gangdong, Seoul

All Listed Sponsors
lead

Hocheol Kim

OTHER

NCT02828540 - Clinical Trial to Assess the Efficacy and to Evaluate Safety of HT047 in Patients With Acute Ischemic Stroke | Biotech Hunter | Biotech Hunter